QVAR / QVAR RediHaler Inhaler Antitrust Class Action Settlement

People who bought, paid for, or were reimbursed for QVAR or QVAR RediHaler asthma inhalers between January 1, 2015 and July 31, 2025 and lived in one of 41 eligible states plus DC. Consumers file by attestation — no receipt required.

• Bought, paid for, or were reimbursed for QVAR or QVAR RediHaler between Jan 1, 2015 and July 31, 2025
• Lived in one of the 41 eligible states or DC
• Consumers file by attestation (no receipt); proof of purchase optional but yields a larger share

Teva agreed to a $35 million settlement to resolve antitrust claims over its QVAR and QVAR RediHaler asthma inhalers. The end-payor lawsuit alleges Teva used product reformulations, strategic patent listings in the FDA's Orange Book, and related litigation to block or delay lower-cost generic QVAR — keeping consumers and insurers paying brand-name prices longer. Teva denies the allegations and is settling without admitting wrongdoing. Beyond the cash fund, Teva reportedly agreed to withdraw certain QVAR-related patents from the Orange Book, which could make it easier for generic QVAR to reach the market.

Who's excluded: Covers 41 states plus DC — a handful of states without indirect-purchaser laws are not included (check the official long-form notice). Excluded are the defendants and their affiliates, government entities, and anyone who validly opts out.

• Consumer claim — no receipt

  Individual consumers file by attestation that they bought QVAR/QVAR RediHaler during the class period — no Claim ID or PIN needed. Pro rata cash from the $35M fund; documented claims (with proof) receive a larger share than attestation-only claims.

• Third-party payors

  Insurers, health plans, and other entities that paid for or reimbursed QVAR file a separate claim and must substantiate their reimbursement data (pharmacy claims records).

1. 1Open the official claim form at QVARAntitrustSettlement.com (or mail the printable form).
2. 2Attest that you bought QVAR during the class period; optionally upload pharmacy receipts, EOBs, or prescription history for a larger share.
3. 3Submit online or postmark by July 31, 2026.

1. Claim deadlineJuly 31, 2026
2. Final approval hearingAugust 5, 2026, Boston, MA

After final approval at the August 5, 2026 hearing, if no appeals are filed the administrator can begin distributing payments within a few months; appeals could push distribution out 12–36 months. Amounts are pro rata and depend on total valid claims and your QVAR spend.

• Official settlement website & claim form
• Administrator: A.B. Data, Ltd.
• Case: Iron Workers District Council of New England Health and Welfare Fund, et al. v. Teva Pharmaceutical Industries Ltd., et al. · No. 1:23-cv-11131-NMG · U.S. District Court, District of Massachusetts